NCT03300687View on ClinicalTrials.gov

First in Human Safety Study of FX-322 in Adults Undergoing Cochlear Implantation

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

May 30, 2017

Primary Completion Date

December 12, 2017

Study Completion Date

January 18, 2018

Conditions
Hearing Loss
Interventions
DRUG

FX-322

intratympanic injection

DRUG

Placebo

intratympanic injection

Trial Locations (1)

Unknown

Royal Victoria Eye and Ear Hospital, Melbourne

Sponsors
All Listed Sponsors
lead

Frequency Therapeutics

INDUSTRY